guest ::
| Home > Publications database > Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review |
| Home > Publications database > Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review |
| Journal Article | FZJ-2024-03594 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2024
Oxford Univ. Press
Oxford
This record in other databases: 
Please use a persistent id in citations: doi:10.1093/neuonc/noae032 doi:10.34734/FZJ-2024-03594
Abstract: Background: The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors.Methods: The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisciplinary Task Force to critically review the role of blood and cerebrospinal fluid (CSF)-liquid biopsy in CNS lymphomas, with a main focus on primary central nervous system lymphomas (PCNSL).Results: Several clinical applications are suggested: diagnosis of PCNSL in critical settings (elderly or frail patients, deep locations, and steroid responsiveness), definition of minimal residual disease, early indication of tumor response or relapse following treatments, and prediction of outcome.Conclusions: Thus far, no clinically validated circulating biomarkers for managing both primary and secondary CNS lymphomas exist. There is need of standardization of biofluid collection, choice of analytes, and type of technique to perform the molecular analysis. The various assays should be evaluated through well-organized central testing within clinical trials.Keywords: CSF biomarkers; MYD88 mutations; circulating tumor DNA; primary CNS lymphomas; secondary CNS lymphomas
; 
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 15 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
PDF